Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jornay PM for ADHD in Pediatric Epilepsy
NCT07594652Phase 4Recruiting
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger
- Start
- May 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Hugo W. Moser Research Institute at Kennedy Krieger. Primary endpoint: Clinical Global Impression-Improvement at 12 weeks. Started May 2026; status: recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07594652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594652.